Go AS, et al
Emerging research suggests that GLP-1RAs may also be beneficial in treating conditions like obstructive sleep apnea (Malhotra et al., 2024), osteoarthritis (Bliddal et al., 2024), metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis with liver fibrosis (MASH) (Loomba et al., 2024), polycystic ovary syndrome (PCOS) (Szczesnowicz et al., 2023), Alzheimers disease (Liang et al., 2024), Parkinsons disease (Kalinderi et al., 2024), and addiction (Klausen et al., 2022)
Circana suggests ramping up the development of high-protein, ready-to-eat meals, and portion-controlled snacks that support both satiety and blood sugar maintenance, while focusing on fibre-rich foods
Ready to get started
At 52 weeks, a reduction in circulating volume and blood pressure is observed, associated with decreased levels of adipokines and aldosterone, alongside reduced albuminuria and increased glomerular filtration rate compared with placebo, suggesting an additional renal benefit.47 GIP antagonist - GLP-1 agonist: MariTida This drug (Maridebart-cafraglutide or AMG 133), which is a conjugate of a monoclonal antibody to the GIP receptor and two GLP-1 receptor agonist molecules, is effective in reducing body weight in obese mice and cynomolgus monkeys
What You Can Do Now If you are an older adult with metabolic risk factors for cognitive decline, discuss the PROTECT-Cog Study with your clinician when enrollment opens
